Ablative fractional CO2 laser for acne scars: 2026 evidence

Ablative fractional carbon dioxide (CO2) laser resurfacing is widely described in the dermatology literature as a well-established — and by several authors, gold-standard — energy-based treatment for atrophic acne scars, which make up an estimated 80–90% of all acne scarring [4]. It pairs the fractional photothermolysis concept with an ablative 10,600-nm wavelength: instead of resurfacing the entire surface, it drills microscopic columns of controlled thermal injury separated by untreated skin, which shortens recovery relative to fully ablative resurfacing while still driving dermal remodeling [1].

This article summarizes what the published clinical literature supports in 2026: mechanism, expected efficacy, the post-inflammatory hyperpigmentation (PIH) risk that dominates decision-making on darker and Asian skin, combination strategies, comparison with other modalities, and patient selection. This is not medical advice; decisions about laser resurfacing should be made with a board-certified dermatologist after a complete skin examination.

At a glance

• What it treats: Atrophic acne scars (rolling, boxcar, and — usually in combination — ice-pick), which are 80–90% of acne scars [4].
• Typical protocol: 1–3 sessions at monthly intervals; three sessions outperformed fewer in an Asian cohort [2].
• Evidence base: A systematic review of 30 studies (18 prospective randomized trials) supports efficacy; parameters must be customized per patient [1].
• Main limitation: Post-inflammatory hyperpigmentation — up to ~73% in one Asian series, lasting >3 months in ~32% [2].
• Downtime: Several days of crusting/erythema; residual redness can persist beyond three months in a minority [2].

Atrophic scars make up most acne scarring, and shape guides device selection: ice-pick scars often need TCA CROSS, boxcar and rolling scars respond to resurfacing, and tethered rolling scars add subcision.

Mechanism

A fractional CO2 laser emits a 10,600-nm beam that is strongly absorbed by tissue water. Delivered fractionally, it creates arrays of microthermal treatment zones — narrow columns of vaporized and thermally coagulated tissue — surrounded by intact skin that serves as a reservoir for rapid re-epithelialization. Each zone triggers a wound-healing cascade: fibroblast activation, neocollagenesis, and dermal matrix remodeling that reorganizes scar collagen over the following weeks to months [1]. Because only a fraction of the surface is ablated per pass, recovery is faster and the complication profile is lower than traditional fully ablative CO2 resurfacing [3].

What the evidence shows

The most comprehensive synthesis is a systematic review of 30 studies (12 retrospective, 18 prospective randomized trials) spanning three decades, which concluded that ablative fractional CO2 laser is an effective therapy for acne scars, that treatment sessions, intervals, and parameters should be customized to each patient, and that combination therapy should be considered for ice-pick scars [1].

Quantitatively, controlled and cohort data report meaningful but partial improvement rather than erasure:

• In an Asian retrospective cohort (Fitzpatrick III–IV), mean ECCA acne-scar scores fell from 102.70 to 87.28 after treatment (p ≤ 0.001), and three sessions were associated with better outcomes than fewer [2].
• In a Singapore series of 107 Asian patients (210 treatments), most reported modest texture improvement — about 66% in the under 25% improvement band and 30% in the 25–50% band — underscoring that ablative fractional CO2 is an incremental, multi-session treatment, not a one-visit fix [3].

The dominant issue on darker and Asian skin: PIH

For patients with Fitzpatrick III–VI skin — including most Korean and many international patients seen in Seoul — post-inflammatory hyperpigmentation is the risk that governs how aggressively the device can be used. The published Asian data make the trade-off explicit:

• In the Fitzpatrick III–IV cohort, PIH affected 73.17% of patients and lasted longer than three months in 31.71%; erythema occurred in all patients and persisted beyond three months in about 20%; post-laser scars occurred in 2.44% [2].
• In the Singapore series treated with more conservative settings, total adverse events were 15%, with PIH in 6.4%, blistering 4.0%, and crusting 2.9% [3].

The practical reading: on darker skin, conservative energy and density, fewer passes, strict photoprotection, and a lower threshold for combination or gentler modalities matter more than chasing maximal single-session ablation. Pigment risk — not efficacy — is usually the limiting factor.

On darker phototypes, pigment risk rather than efficacy usually sets the ceiling on how aggressively fractional CO2 can be used.

Combination and adjuvant strategies

Because ablative fractional CO2 is effective but pigment- and downtime-limited, much of the recent evidence tests adjuvants that either boost remodeling or blunt the inflammatory aftermath:

• Platelet-rich plasma (PRP): A meta-analysis of 11 randomized trials (313 participants) found that adding PRP to ablative fractional CO2 laser significantly improved clinical response versus laser alone (odds ratio 2.56, 95% CI 1.37–4.78) and patient satisfaction (OR 3.38) [4].
• Hyaluronic acid dressing: A meta-analysis of 6 studies (623 patients) found that a post-laser HA dressing lowered ECCA scores further (mean difference −3.37), shortened crust formation and removal time, and — notably — reduced the incidence of hyperpigmentation versus laser alone (risk ratio 0.37, 95% CI 0.23–0.61) [5].
• Stem cell-derived exosomes: A double-blind, randomized, split-face trial reported greater ECCA-score reduction on the exosome-treated side than control (32.5% vs 19.9%, p < 0.01), with milder erythema and shorter downtime [6].

These adjuvants share a theme relevant to darker skin: several reduce downtime and pigmentary risk rather than only adding efficacy.

How it compares with other modalities

A systematic review comparing needling with ablative fractional lasers found no statistically significant difference in 60% of studies, with both producing significant improvement [7] — reinforcing that scar type, skin tone, and downtime tolerance, not a single "best device," should drive the plan.

Patient selection and who should defer

Commonly cited reasons to modify, delay, or avoid ablative fractional CO2 resurfacing include active local infection or inflammatory acne in the treatment area, recent isotretinoin use per clinician judgment, a history of keloid or hypertrophic scarring, and darker skin phototypes without a conservative, pigment-aware plan [1][2]. A realistic consultation sets expectations around multiple sessions, weeks of erythema, and the specific PIH risk for the patient's skin tone.

Bottom line

Ablative fractional CO2 laser is a well-supported, effective treatment for atrophic acne scars, but the honest 2026 picture is incremental improvement across several sessions, with post-inflammatory hyperpigmentation as the dominant constraint on darker and Asian skin. Conservative parameters, photoprotection, and evidence-backed adjuncts (HA dressing, PRP, exosomes) improve the efficacy-to-downtime ratio. For a full picture of how this fits alongside subcision, TCA CROSS, microneedling RF, and fillers, see our overview of atrophic acne scar types and treatment.